These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 29304946)

  • 41. Traditional Chinese Medicine treatment as maintenance therapy in advanced non-small-cell lung cancer: A randomized controlled trial.
    Jiang Y; Liu LS; Shen LP; Han ZF; Jian H; Liu JX; Xu L; Li HG; Tian JH; Mao ZJ
    Complement Ther Med; 2016 Feb; 24():55-62. PubMed ID: 26860802
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Efficacy of erlotinib in patients with advanced non-small cell lung cancer: a pooled analysis of randomized trials.
    Gao H; Ding X; Wei D; Cheng P; Su X; Liu H; Aziz F; Wang D; Zhang T
    Anticancer Drugs; 2011 Oct; 22(9):842-52. PubMed ID: 21808188
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Exploration of modified progression-free survival as a novel surrogate endpoint for overall survival in immuno-oncology trials.
    Wang ZX; Wu HX; Xie L; Lin WH; Liang F; Li J; Yang ZM; Xu RH
    J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33795385
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Long-term outcomes in radically treated synchronous vs. metachronous oligometastatic non-small-cell lung cancer.
    Fleckenstein J; Petroff A; Schäfers HJ; Wehler T; Schöpe J; Rübe C
    BMC Cancer; 2016 Jun; 16():348. PubMed ID: 27255302
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Surrogate endpoints for overall survival in anti-programmed death-1 and anti-programmed death ligand 1 trials of advanced melanoma.
    Nie RC; Yuan SQ; Wang Y; Zou XB; Chen S; Li SM; Duan JL; Zhou J; Chen GM; Luo TQ; Zhou ZW; Li YF
    Ther Adv Med Oncol; 2020; 12():1758835920929583. PubMed ID: 32595775
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Surrogate End Points for Overall Survival in Metastatic, Locally Advanced, or Unresectable Pancreatic Cancer: A Systematic Review and Meta-Analysis of 24 Randomized Controlled Trials.
    Makris EA; MacBarb R; Harvey DJ; Poultsides GA
    Ann Surg Oncol; 2017 Aug; 24(8):2371-2378. PubMed ID: 28397190
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Clinical impact of postprogression survival for overall survival in elderly patients (aged 75 years or older) with advanced nonsmall cell lung cancer.
    Yoshino R; Imai H; Mori K; Tomizawa Y; Takei K; Tomizawa M; Kaira K; Yoshii A; Watanabe S; Saito R; Yamada M
    J Cancer Res Ther; 2015; 11(3):606-11. PubMed ID: 26458589
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Erlotinib-based targeted dual agent versus erlotinib alone in previously treated advanced non-small-cell lung cancer: a meta-analysis of 13 randomized controlled trials.
    Yu S; Xu Q; Yuan Y; Li X; Cai H
    Curr Med Res Opin; 2016 Dec; 32(12):1927-1934. PubMed ID: 27479336
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Prognostic and predictive effects of TP53 co-mutation in patients with EGFR-mutated non-small cell lung cancer (NSCLC).
    Labbé C; Cabanero M; Korpanty GJ; Tomasini P; Doherty MK; Mascaux C; Jao K; Pitcher B; Wang R; Pintilie M; Leighl NB; Feld R; Liu G; Bradbury PA; Kamel-Reid S; Tsao MS; Shepherd FA
    Lung Cancer; 2017 Sep; 111():23-29. PubMed ID: 28838393
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Dual inhibiting EGFR and VEGF pathways versus EGFR-TKIs alone in the treatment of advanced non-small-cell lung cancer: a meta-analysis of randomized controlled trials.
    Zhang TT; Wang RM; Yang Z; Chen GB
    Clin Transl Oncol; 2016 Jun; 18(6):576-81. PubMed ID: 26527033
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Can Aidi injection improve overall survival in patients with non-small cell lung cancer? A systematic review and meta-analysis of 25 randomized controlled trials.
    Xiao Z; Wang C; Zhou R; Hu S; Yi N; Feng J; Zhou M; Liu S; Chen L; Ding J; Gong Q; Tang F; Li X
    Complement Ther Med; 2018 Apr; 37():50-60. PubMed ID: 29609937
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Efficacy and prognostic factors of 178 advanced non-small lung cancer patients undergoing different second-line chemotherapeutic regimens].
    Kong Q; Wang XY; Jiang RC; Ba Y; Li K
    Zhonghua Zhong Liu Za Zhi; 2016 Apr; 38(4):294-9. PubMed ID: 27087377
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Chemotherapy with or without gefitinib in patients with advanced non-small-cell lung cancer: a meta-analysis of 6,844 patients.
    Zhou H; Zeng C; Wang LY; Xie H; Zhou J; Diao P; Yao WX; Zhao X; Wei Y
    Chin Med J (Engl); 2013; 126(17):3348-55. PubMed ID: 24033963
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Final survival and safety results from a multicenter, open-label, phase 3b trial of erlotinib in patients with advanced nonsmall cell lung cancer.
    Spigel DR; Lin M; O'Neill V; Hainsworth JD
    Cancer; 2008 Jun; 112(12):2749-55. PubMed ID: 18438878
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Magnitude of the benefit of progression-free survival as a potential surrogate marker in phase 3 trials assessing targeted agents in molecularly selected patients with advanced non-small cell lung cancer: systematic review.
    Hotta K; Kato Y; Leighl N; Takigawa N; Gaafar RM; Kayatani H; Hirata T; Ohashi K; Kubo T; Tabata M; Tanimoto M; Kiura K
    PLoS One; 2015; 10(3):e0121211. PubMed ID: 25775395
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Systems assessment of intercalated combination of chemotherapy and EGFR TKIs versus chemotherapy or EGFR TKIs alone in advanced NSCLC patients.
    Yan H; Li Q; Wang W; Zhen H; Cao B
    Sci Rep; 2015 Oct; 5():15355. PubMed ID: 26481697
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Intercalated Combination of Chemotherapy and EGFR-TKIs versus Chemotherapy Alone in the First-line Treatment of Advanced Non-small Cell Lung Cancer: A Meta-analysis].
    Hong C; Mei T; Wang J
    Zhongguo Fei Ai Za Zhi; 2016 Dec; 19(12):837-846. PubMed ID: 27978869
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Intermediate clinical endpoints: a bridge between progression-free survival and overall survival in ovarian cancer trials.
    Matulonis UA; Oza AM; Ho TW; Ledermann JA
    Cancer; 2015 Jun; 121(11):1737-46. PubMed ID: 25336142
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The efficacy and safety of pemetrexed-based doublet therapy compared to pemetrexed alone for the second-line treatment of advanced non-small-cell lung cancer: an updated meta-analysis.
    Zhong A; Xiong X; Shi M; Xu H
    Drug Des Devel Ther; 2015; 9():3685-93. PubMed ID: 26229433
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Gefitinib or Erlotinib vs Chemotherapy for EGFR Mutation-Positive Lung Cancer: Individual Patient Data Meta-Analysis of Overall Survival.
    Lee CK; Davies L; Wu YL; Mitsudomi T; Inoue A; Rosell R; Zhou C; Nakagawa K; Thongprasert S; Fukuoka M; Lord S; Marschner I; Tu YK; Gralla RJ; Gebski V; Mok T; Yang JC
    J Natl Cancer Inst; 2017 Jun; 109(6):. PubMed ID: 28376144
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.